v3.22.1
Consolidated Balance Sheets - USD ($)
Mar. 31, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 8,440,952 $ 12,264,736
Unbilled receivable 808,601 441,721
Right-of-use asset 17,609 24,721
Prepaid expenses and other current assets 2,391,240 2,931,415
Total current assets 11,658,402 15,662,593
Property and equipment, net
Other assets 713,090 754,756
Total assets 12,371,492 16,417,349
Current liabilities:    
Accounts payable 959,630 301,104
Accrued expenses and other liabilities 1,751,506 3,407,533
Lease liability 17,716 24,874
Notes payable and accrued interest ($6,073,057 and $12,358,886 at fair value at March 31, 2022 and December 31, 2021, respectively) 6,073,057 12,748,155
Total current liabilities 8,801,909 16,481,666
Long-term liabilities:    
Notes payable, net of current portion (at fair value) 1,586,901 4,440,951
Other long-term liabilities 871,409 3,652,790
Total long-term liabilities 2,458,310 8,093,741
Total liabilities 11,260,219 24,575,407
Commitments and contingencies (Note 6)
Stockholders’ equity (deficit)    
Preferred stock, $0.0001 par value, 1,500,000 shares authorized, no shares issued and outstanding at March 31, 2022 (unaudited) and December 31, 2021
Common stock, $0.0001 par value, 150,000,000 shares authorized; 29,968,787 and 24,662,904 shares issued at March 31, 2022 (unaudited) and December 31, 2021, respectively; 29,949,032 and 24,643,149 shares outstanding at March 31, 2022 (unaudited) and December 31, 2021, respectively 2,995 2,464
Additional paid-in capital 88,900,164 77,964,860
Accumulated deficit (87,512,253) (85,845,567)
Total Ensysce Biosciences, Inc. stockholders’ equity (deficit) 1,390,906 (7,878,243)
Noncontrolling interests in stockholders’ equity (deficit) (279,633) (279,815)
Total stockholders’ equity (deficit) 1,111,273 (8,158,058)
Total liabilities and stockholders’ equity (deficit) $ 12,371,492 $ 16,417,349

Source